Literature DB >> 33678521

Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma?

Diego Aguilar Palacios1, Emily C Zabor2, Carlos Munoz-Lopez1, Gustavo Roversi1, Furman Mahmood1, Emily Abramczyk1, Maureen Kelly1, Brigid Wilson3, Robert Abouassaly4, Steven C Campbell5.   

Abstract

BACKGROUND: Recent publications have reported an association between increased renal cancer-specific mortality (CSM) and reduced renal function "below safety limits," and advocated for partial nephrectomy (PN) even for potentially aggressive/complex tumors. We hypothesize that this association may be related to confounding factors rather than a consequence of functional differences.
OBJECTIVE: To assess whether there is an independent association between preoperative estimated glomerular filtration rate (eGFR) or new baseline eGFR (NB-GFR) and CSM in patients undergoing PN or radical nephrectomy (RN). DESIGN, SETTING, AND PARTICIPANTS: A single-center retrospective review was performed. All clinically and pathologically confirmed T1-T3a/N0/M0 renal cancer patients undergoing PN/RN (1999-2008, n = 1605) with adequate functional/oncological data were included. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was CSM. Secondary endpoints were cancer recurrence (CR) and all-cause mortality (ACM). Cox regression analyses investigated endpoints and predictive factors. RESULTS AND LIMITATIONS: The median age was 60 yr and 64% of patients were male. Comorbidities included hypertension (60%), cardiovascular disease (19%), diabetes (21%), and chronic kidney disease (22%). PN was performed in 954 patients (59%). The median preoperative eGFR and NB-GFR were 80 and 60 ml/min/1.73 m2, respectively. Median tumor diameter was 3.6 cm (interquartile range [IQR] = 2.4, 5.5); 70% of tumors were clear cell and 40% were of high grade. Pathology revealed pT1-2/N0/M0 and pT3a/N0/M0 in 81% and 19%, respectively. The median follow-up among survivors was 11.5 yr (IQR = 4, 14). Cancer-specific survival, recurrence-free survival, and overall survival were 94%, 88%, and 73% at 10 yr, respectively. On multivariable analysis, increased age (hazard ratio [HR] = 1.03, p =  0.04), increased tumor size (HR = 1.24, p <  0.01), tumor grade 3/4 (HR = 3.17, p <  0.01), and clear-cell histology (HR = 2.92, p <  0.01) were associated with increased hazard of CSM. Neither preoperative eGFR nor NB-GFR was significantly associated with CSM or CR (all p >  0.1), while an increased preoperative eGFR was associated with reduced hazard of ACM (HR = 0.87, p <  0.01). Limitations include retrospective design and a potential selection bias.
CONCLUSIONS: Our data do not support oncological protection of greater preservation of renal function and confirm that unfavorable oncological outcomes for localized RCC are mostly associated with aggressive tumor characteristics. PATIENT
SUMMARY: We did not find an association between greater preservation of renal function and oncological outcomes for kidney cancer.
Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Kidney cancer; Mortality and renal function; Nephrectomy

Mesh:

Substances:

Year:  2021        PMID: 33678521     DOI: 10.1016/j.eururo.2021.02.035

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

1.  External validation of the Palacios' equation: a simple and accurate tool to estimate the new baseline renal function after renal cancer surgery.

Authors:  Alessandro Tafuri; Marco Sandri; Alberto Martini; Umberto Capitanio; Guglielmo Mantica; Carlo Terrone; Maria Furlan; Claudio Simeone; Daniele Amparore; Francesco Porpiglia; Andrea Minervini; Andrea Mari; Maria Angela Cerruto; Alessandro Antonelli
Journal:  World J Urol       Date:  2021-11-26       Impact factor: 4.226

2.  Global Analysis of Research Trends on Kidney Function After Nephron-Sparing Surgery: A Bibliometric and Visualised Study.

Authors:  Faris Abushamma; Abdulkarim Barqawi; Samah W Al-Jabi; Maha Akkawi; Mosab Maree; Sa'ed H Zyoud
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

3.  Partial and Radical Nephrectomy Provides Equivalent Oncologic Outcomes in pT3a Renal Cell Carcinoma: A Population-Based Study.

Authors:  Jihua Tian; Xing Zeng; Jie Wan; Jiahua Gan; Chunjin Ke; Wei Guan; Zhiquan Hu; Chunguang Yang
Journal:  Front Oncol       Date:  2022-01-26       Impact factor: 6.244

4.  Stress Reactivity, Susceptibility to Hypertension, and Differential Expression of Genes in Hypertensive Compared to Normotensive Patients.

Authors:  Dmitry Oshchepkov; Irina Chadaeva; Rimma Kozhemyakina; Karina Zolotareva; Bato Khandaev; Ekaterina Sharypova; Petr Ponomarenko; Anton Bogomolov; Natalya V Klimova; Svetlana Shikhevich; Olga Redina; Nataliya G Kolosova; Maria Nazarenko; Nikolay A Kolchanov; Arcady Markel; Mikhail Ponomarenko
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

5.  Partial Nephrectomy Versus Radical Nephrectomy for Endophytic Renal Tumors: Comparison of Operative, Functional, and Oncological Outcomes by Propensity Score Matching Analysis.

Authors:  Situ Xiong; Ming Jiang; Yi Jiang; Bing Hu; Ru Chen; Zhijun Yao; Wen Deng; Xianwen Wan; Xiaoqiang Liu; Luyao Chen; Bin Fu
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

6.  Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Con.

Authors:  Teele Kuusk; Axel Bex
Journal:  Eur Urol Open Sci       Date:  2022-08-30

7.  MiRNA-148a inhibits cell growth and drug resistance by regulating WNT10a expression in renal cell carcinoma.

Authors:  Yongsheng Chen; Wenhua Liu; Dechao Li; Yan Cao; Wentao Wang; Changfu Li; Ruihua An
Journal:  Transl Androl Urol       Date:  2022-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.